论文部分内容阅读
目的:探讨不同剂量重组人粒细胞集落刺激因子(rhG-CSF)对大剂量阿糖胞苷化疗后白细胞减少的疗效。方法:60例入选对象,随机分为A、B、C 3组,在白细胞下降开始分别予rhG-CSF 300μg.d-1、450μg.d-1、300μg.(12 h)-1皮下注射,至白细胞恢复至正常值4.0×109L-1时即停药,记录白细胞恢复所需时间及用药期间的不良反应,同时观察中性粒细胞计数。结果:A、B、C组治疗时间分别为(13.3±8.0)、(12.8±3.7)、(11.9±2.4)d;A、B组不良反应发生率差异无统计学意义;C组治疗时间与B组差异无统计学意义,但不良反应发生率高于A、B组(P<0.05);中性粒细胞计数B、C组与A组比较差异均有统计学意义(P<0.05)。结论:对大剂量阿糖胞苷化疗后白细胞减少患者予300μg.d-1rhG-CSF治疗,白细胞及中性粒细胞计数回升时间快,且不良反应较少,可以作为常规治疗剂量。
Objective: To investigate the effect of different doses of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukopenia after high-dose cytarabine chemotherapy. Methods: Sixty subjects were randomly divided into A, B and C groups, and received rhG-CSF 300μg.d-1,450μg.d-1,300μg. (12h) -1 subcutaneously at the start of leukopenia. To the white blood cells returned to normal when the value of 4.0 × 109L-1 when the withdrawal, recording the time required for recovery of leukocytes and medication during the adverse reactions, and observe the neutrophil count. Results: The treatment time in group A, B and C were (13.3 ± 8.0) and (12.8 ± 3.7) and (11.9 ± 2.4) days, respectively. There was no significant difference in the incidence of adverse reactions between groups A and B There was no significant difference between group B and group B, but the incidence of adverse reactions was higher than that of group A and B (P <0.05). The difference of neutrophil count between group B and C was statistically significant (P <0.05). Conclusion: The treatment of 300 μg.d-1 rhG-CSF in patients with leukopenia after high-dose cytarabine chemotherapy has faster recovery time of leucocyte and neutrophil counts with less adverse reactions and can be used as a routine treatment dose.